Enhanced Immunogenicity to
            <i>Mycobacterium tuberculosis</i>
            by Vaccination with an Alphavirus Plasmid Replicon Expressing Antigen 85A

Kirman, Joanna R.; Turon, Tara N.; Su, Huawei; Li, Amy; Kraus, Carl; Polo, John M.; Belisle, John T.; Morris, Sheldon L.; Seder, Robert A.

doi:10.1128/iai.71.1.575-579.2003

Cited by 59 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, multiple CpG motifs can be added to the DNA backbone to increase its adjuvant effects. Furthermore, the development of new DNA vaccines that incorporate the Sindbis virus RNA replicase increase the immunogenicity of conventional DNA vaccines and allow lower doses of DNA to be administered [100]. For example, Derrick et al found that a Sindbis virus-based DNA vaccine encoding the M. tuberculosis Ag85B was able to provide protection comparable to that of BCG based both on a reduction in CFU and a prolongation in survival [29].…”

Section: Dna Vaccinationmentioning

confidence: 99%

“…Vaccination with plasmid DNA encoding 72F elicits a robust CTL response against Mtb32 [93][94][95][96][97][98][99][100][101][102] and generates protective immunity in both mice and guinea pigs [87]. Interestingly, when the vaccine is formulated as a polyprotein vaccine, it elicits a strong CTL response against Mtb32 [93][94][95][96][97][98][99][100][101][102] , an epitope that elicits CD8 + T cells after DNA vaccination. A critical variable appears to be the adjuvant -and the adjuvant AS01B seems to be particularly effective at stimulating a CD8 + T cell response.…”

Section: Subunit Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Behar

Woodworth

2007

Expert Review of Vaccines

View full text Add to dashboard Cite

SummaryTuberculosis continues to cause considerable human morbidity and mortality across the world, particularly in people coinfected with HIV. The emergence of multidrug resistance makes the medical treatment of tuberculosis even more difficult. Thus, the development of a tuberculosis vaccine is a global health priority. Here we review the data concerning the role of CD8 + T cells in immunity to tuberculosis and consider how CD8 + T cells can be elicited by vaccination. Many immunization strategies have the potential to elicit CD8 + T cells, and we critically review the data supporting a role for vaccine-induced CD8 + T cells in protective immunity. The synergy between CD4 + and CD8 + T cells suggests that a vaccine which elicits both T cell subsets has the best chance at preventing tuberculosis.

show abstract

Section: Dna Vaccinationmentioning

confidence: 99%

Section: Subunit Vaccinesmentioning

confidence: 99%

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Behar

Woodworth

2007

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…To enhance the immunogenicty of genetic immunization, other vectors expressing M. tuberculosis antigens have been tested, such as alphavirus [62,63], adenovirus [64], or vaccinia virus [65]. The use of these viral-based vectors is under consideration in prime-boosting strategies to enhance an antigen-specific immune response.…”

Section: Dna Vaccinesmentioning

confidence: 99%

The quest for a new vaccine against tuberculosis

Delogu

Fadda

2009

J Infect Dev Ctries

View full text Add to dashboard Cite

Tuberculosis (TB) is still one of the deadliest human diseases, killing 1,6 million people each year, mostly in developing countries. The vaccine currently used, Bacille Calmette and Guerin (BCG), is effective in preventing the most severe disseminated forms of disease in children and newborns, but its efficacy against active TB in adults has been challenged by several clinical studies. It is a common opinion that only the development of a new and more effective vaccine against TB would significantly ease the pandemic. In the last few years, the search for a new vaccine has gained a new momentum. New live and attenuated strains of M. tuberculosis, improved recombinant BCG strains and subunit vaccines have been tested in preclinical animal models, and some of them showed promising results. Unfortunately, the lack of immunological correlates of protection makes very difficult to anticipate or foresee the efficacy of any of these new vaccines and only phase III clinical trials, that are expected to start in 2009 and last few years, will tell us the real value of these new prophylactic tools. This review highlights the different strategies that are being implemented for the development of an improved vaccine against TB, the rationale behind them and the potential and feasible vaccination schedules that could be implemented.

show abstract

“…Several groups have demonstrated the ability of suicidal DNA vaccines to induce high-level humoral and cellmediated immunity against a variety of antigens, with immunized animals developing more prominent immune responses than those receiving a conventional DNA vaccine encoding the same antigen (Berglund et al, 1998;Deshpande et al, 2002;Hariharan et al, 1998;Kirman et al, 2003;Leitner et al, 2000). In addition, it has been demonstrated that suicidal DNA vaccines could break immunological tolerance by activating innate antiviral pathways, in contrast to conventional DNA vaccines encoding the same antigen (Leitner et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

“…The RNA selfamplifying property is of considerable interest with respect to vaccine biosafety: the vector replicates at the RNA level and not at the DNA level, so the rate of foreign DNA present in vivo and possessing 'genome integration potential' is controlled and does not increase following vaccination (contrary to some attenuated or recombinant vaccines). Furthermore, when a suicidal DNA vaccine is transfected into cells, it leads eventually to apoptosis of the transfected cells (Kohno et al, 1998;Leitner et al, 2000), which is particularly important in alleviating the concerns of potential integration and cell transformation generated by the use of conventional DNA vaccines (Gurunathan et al, 2000;Lewis & Babiuk, 1999).Several groups have demonstrated the ability of suicidal DNA vaccines to induce high-level humoral and cellmediated immunity against a variety of antigens, with immunized animals developing more prominent immune responses than those receiving a conventional DNA vaccine encoding the same antigen (Berglund et al, 1998;Deshpande et al, 2002;Hariharan et al, 1998;Kirman et al, 2003;Leitner et al, 2000). In addition, it has been demonstrated that suicidal DNA vaccines could break immunological tolerance by activating innate antiviral pathways, in contrast to conventional DNA vaccines encoding the same antigen (Leitner et al, 2003).…”

mentioning

confidence: 99%

Protective immune responses in guinea pigs and swine induced by a suicidal DNA vaccine of the capsid gene of swine vesicular disease virus

Sun

Liu

Guo

et al. 2007

Journal of General Virology

View full text Add to dashboard Cite

A suicidal DNA vaccine based on a Semliki Forest virus (SFV) replicon was evaluated for the development of a vaccine against swine vesicular disease virus (SVDV). The 1BCD gene of SVDV was cloned and inserted into pSCA1, an SFV DNA-based replicon vector. The resultant plasmid, pSCA/1BCD, was transfected into BHK-21 cells and the antigenicity of the expressed protein was confirmed using an indirect immunofluorescence assay. Immunogenicity was studied in guinea pigs and swine. Animals were injected intramuscularly three times with pSCA/1BCD at regular intervals. Anti-SVDV antibodies were detected by ELISA, the lymphocyte proliferation response was tested by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide method and neutralizing antibodies were measured by microneutralization tests. The data showed that SVDV-specific antibodies, neutralizing antibodies and lymphocyte proliferation were induced in both guinea pigs and swine. Furthermore, after three successive vaccinations with pSCA/1BCD, half of the pigs were protected against challenge with SVDV. These results should encourage further work towards the development of a DNA vaccine against SVDV. INTRODUCTIONSwine vesicular disease (SVD) is a highly contagious viral pig disease, characterized by the appearance of vesicles on the coronary bands, heels of the feet and less commonly on the snout and tongue. Due to the similarity of these lesions to those caused by foot-and mouth-disease (FMD), SVD is subject to international controls and is listed by the World Organization for Animal Health. SVD was first identified in Italy in 1966(Nardelli et al., 1968 and several more outbreaks have been reported subsequently in Europe and eastern Asia (Brocchi et al., 1997). However, in the recent past, reports of SVD have been limited to Portugal and Italy.SVD vaccines have been developed previously to control the disease, both in monovalent form (Gourreau et al., 1975) and in combination with FMD (Mitev et al., 1978), and an SVD subunit vaccine has also been described, although it was not very efficacious (Jiménez-Clavero et al., 1998). Although the inactivated virus vaccines are effective in protecting against clinical signs, there has been little, if any, assessment made of their ability to reduce wild-type virus transmission and no effective vaccine is available commercially. Once introduced, SVD could be a difficult disease to eradicate and improved methods of control would be highly beneficial, including the development of safer and more effective vaccines to protect and control this disease.Suicidal DNA vaccines, based on the alphavirus replicon, have emerged as an important strategy to enhance immunogenicity and to improve the biosafety of conventional DNA vaccines (Berglund et al., 1998;Leitner et al., 1999;Lundstrom, 2000). Unlike the conventional DNA vaccine construct in which heterologous gene expression is driven directly by the RNA polymerase II-dependent promoter, suicidal DNA vaccines based on the replicon of alphaviruses, including Sindbis viru...

show abstract

Enhanced Immunogenicity to Mycobacterium tuberculosis by Vaccination with an Alphavirus Plasmid Replicon Expressing Antigen 85A

Cited by 59 publications

References 19 publications

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

The quest for a new vaccine against tuberculosis

Protective immune responses in guinea pigs and swine induced by a suicidal DNA vaccine of the capsid gene of swine vesicular disease virus

Contact Info

Product

Resources

About

Enhanced Immunogenicity to Mycobacterium tuberculosis by Vaccination with an Alphavirus Plasmid Replicon Expressing Antigen 85A

Cited by 59 publications

References 19 publications

Next generation: tuberculosis vaccines that elicit protective CD8+T cells

Next generation: tuberculosis vaccines that elicit protective CD8+T cells

The quest for a new vaccine against tuberculosis

Protective immune responses in guinea pigs and swine induced by a suicidal DNA vaccine of the capsid gene of swine vesicular disease virus

Contact Info

Product

Resources

About

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells